Lipids, metabolic syndrome, and risk factors for future cardiovascular disease among HIV-infected patients
- 1 September 2005
- journal article
- review article
- Published by Springer Nature in Current HIV/AIDS Reports
- Vol. 2 (3) , 132-139
- https://doi.org/10.1007/s11904-005-0006-6
Abstract
No abstract availableKeywords
This publication has 50 references indexed in Scilit:
- Metabolic syndrome: Definition, pathophysiology, and mechanismsAmerican Heart Journal, 2005
- Prevalence of coronary heart disease and carotid arterial thickening in patients with the metabolic syndrome (The ARIC Study)The American Journal of Cardiology, 2004
- Nevirapine and Efavirenz Elicit Different Changes in Lipid Profiles in Antiretroviral- Therapy-Naive Patients Infected with HIV-1PLoS Medicine, 2004
- Long‐Term Efficacy and Safety of Protease Inhibitor Switching to Nevirapine in HIV‐Infected Patients with Undetectable Virus LoadClinical Infectious Diseases, 2004
- Efficacy and Safety of Tenofovir DF vs Stavudine in Combination Therapy in Antiretroviral-Naive PatientsA 3-Year Randomized TrialJAMA, 2004
- Increased VLDL-apoB and IDL-apoB production rates in nonlipodystrophic HIV-infected patients on a protease inhibitor-containing regimenJournal of Lipid Research, 2003
- Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)JAMA, 2001
- Atorvastatin and gemfibrozil for protease-inhibitor-related lipid abnormalitiesThe Lancet, 1998
- Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)The Lancet, 1998
- Coronary lesions in young HIV-positive subjects at necropsyThe Lancet, 1992